Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 131–140 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 131
- Medicine slug
- atomoxetine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 50
- Source count
- 50
- Agreement rate
- 1
- Recorded readings
63%
- Numeric value
- 63
- Unit
- %
- Source records
- 50
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 50 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7f78a37-d525-42b7-813a-fa3e18ae7b74 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d7ea8f7-981c-4acc-aeaf-7516325bfc0c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:309de576-c318-404a-bc15-660c2b1876fb (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Parameter Other CYP2D6 Metabolizer Types a CYP2D6 Poor Metabolizers b Absorption Dose proportionality 10-120 mg Accumulation 1.1-fold 3.3-fold Absolute bioavailability 63% 94% T max median 1 hour 2.5 hour Effect of Food AUC: Unchanged;
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa109260-6d4c-429c-9957-19cbe0e34485 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402711d7-bd44-4f2a-ad2b-4756cdc68645 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793928fb-fbcb-4fc6-90d4-f8a15e6b1f93 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb2a8f6-0816-47b1-830a-ef23e97d498f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16096e9c-2dcd-4c84-a1a8-1c85d6d6898c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Table 11: Atomoxetine and Metabolite Pharmacokinetics in Adult CYP2D6 Poor Metabolizers and Other CYP2D6 Metabolizer Types Parameter Other CYP2D6 Metabolizer Types a CYP2D6 Poor Metabolizers b Absorption Dose proportionality 10-120 mg Accumulation 1.1-fold 3.3-fold Absolute bioavailability 63% 94% T max 1 hour - Effect of Food AUC: Unchanged;
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b757805-eabf-4301-85be-7a3e38f6b187 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Parameter Other CYP2D6 Metabolizer Types a CYP2D6 Poor Metabolizers b Absorption Dose proportionality 10-120 mg Accumulation 1.1-fold 3.3-fold Absolute bioavailability 63% 94% Tmax median 1 hour 2.5 hour Effect of Food AUC: Unchanged;
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d26aff3-72a7-4a5b-a6fe-44dc8a08b196 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0782204e-56a3-4439-9fb8-194da9487049 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24bb7238-7e12-48d1-a572-2c753e69f604 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2614df7e-0b16-4b03-883e-141d4ec34b35 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4fe9217-1853-4f8b-9a93-77e511554ca1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1f858c-8721-49e3-be8b-bf180e89ff42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2c12e4-563c-417e-bee1-6d8c51e75af4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9df4617-b406-70ba-e053-2995a90a28e8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14f2804d-2914-4dd9-86c0-d084fcfd7e50 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd1d85-fbc1-4309-9365-58bacf108f5b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cceab35-dc4a-40bc-a245-10b64820e217 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f266ab7b-5a68-42b5-b204-e3249bea0aed (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96855061-440f-4c99-a152-cf8da8e2b1b3 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7002d75-edad-4141-91bf-7eebf50ad1aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e9e305-8d99-4234-b531-6ade177768b7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab8d905-e890-4e91-a730-3e5d12f5c23f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdcc267-d6ae-41ee-97d9-2c7596545ce8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6542d69-d0a2-4663-9172-943f9f6f5325 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e787cc2-5d0f-f231-e053-2a95a90ae99a (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b42f0c-a183-478b-bced-652dc12b33ec (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90f45a1e-f79f-468f-b21b-5dc82f5717aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10d36b32-0202-4c03-8a1a-cd5d53f231e7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution – Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b10860-aa08-4480-816c-c207819e5f9e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14fb8a4c-c2bf-4d44-bea9-cd159c2ca5fa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75bc8e2-8e8e-4883-be9c-b716842c5277 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f98c3424-1c43-43e4-8bca-2e3430f50c63 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a20478-5f33-4ecd-b5d3-dbba855e5f6b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4953df7b-ccdb-452c-8699-5fd7259609b4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d3d8cf-7f3b-479e-bd9f-e204d4118517 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Table 11: Atomoxetine and Metabolite Pharmacokinetics in Adult CYP2D6 Poor Metabolizers and Other CYP2D6 Metabolizer Types Parameter Other CYP2D6 Metabolizer Types a CYP2D6 Poor Metabolizers b Absorption Dose proportionality 10-120 mg Accumulation 1.1-fold 3.3-fold Absolute bioavailability 63% 94% T max 1 hour - Effect of Food AUC: Unchanged;
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc7ba02c-bdbb-5136-e053-2995a90ac545 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f6faeb-52b5-4b04-bf34-de5db8eb46dc (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f89c7c9-4c25-4ba2-ad90-5aeadb48f214 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f14ced9-c16c-905a-e053-2a91aa0a031e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00eb367-d7cc-42fa-91af-a1a5f90dbb41 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and Distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:133a4b65-762b-4712-baba-2442546f0379 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:132852a6-5bff-15dd-255c-98309dd83630 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Table 9: Atomoxetine and Metabolite Pharmacokinetics in Adult CYP2D6 Poor Metabolizers and Other CYP2D6 Metabolizer Types Parameter Other CYP2D6 Metabolizer Types a CYP2D6 Poor Metabolizers b Absorption Dose proportionality 10 to 120 mg Accumulation 1.1-fold 3.3-fold Absolute bioavailability 63% 94% T max median 1 hour 2.5 hour Effect of Food AUC: Unchanged;
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973bdc9b-6421-7e00-e2b6-3cce036d363e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution - Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddec2943-483d-403a-838c-cbdb6eefe0a1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652cb30f-4368-4009-93a3-3a0d2a365f42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a4aa63-0877-40e5-94c4-ea487db5691d (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Absorption and distribution — Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in Ems and 94% in PMs.
Projected row 132
- Medicine slug
- atomoxetine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 50
- Source count
- 45
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 45
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 45 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7f78a37-d525-42b7-813a-fa3e18ae7b74 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d7ea8f7-981c-4acc-aeaf-7516325bfc0c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa109260-6d4c-429c-9957-19cbe0e34485 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402711d7-bd44-4f2a-ad2b-4756cdc68645 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793928fb-fbcb-4fc6-90d4-f8a15e6b1f93 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb2a8f6-0816-47b1-830a-ef23e97d498f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d26aff3-72a7-4a5b-a6fe-44dc8a08b196 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0782204e-56a3-4439-9fb8-194da9487049 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24bb7238-7e12-48d1-a572-2c753e69f604 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2614df7e-0b16-4b03-883e-141d4ec34b35 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4fe9217-1853-4f8b-9a93-77e511554ca1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1f858c-8721-49e3-be8b-bf180e89ff42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2c12e4-563c-417e-bee1-6d8c51e75af4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9df4617-b406-70ba-e053-2995a90a28e8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14f2804d-2914-4dd9-86c0-d084fcfd7e50 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd1d85-fbc1-4309-9365-58bacf108f5b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cceab35-dc4a-40bc-a245-10b64820e217 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f266ab7b-5a68-42b5-b204-e3249bea0aed (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96855061-440f-4c99-a152-cf8da8e2b1b3 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7002d75-edad-4141-91bf-7eebf50ad1aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e9e305-8d99-4234-b531-6ade177768b7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab8d905-e890-4e91-a730-3e5d12f5c23f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdcc267-d6ae-41ee-97d9-2c7596545ce8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6542d69-d0a2-4663-9172-943f9f6f5325 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e787cc2-5d0f-f231-e053-2a95a90ae99a (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b42f0c-a183-478b-bced-652dc12b33ec (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90f45a1e-f79f-468f-b21b-5dc82f5717aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10d36b32-0202-4c03-8a1a-cd5d53f231e7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b10860-aa08-4480-816c-c207819e5f9e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14fb8a4c-c2bf-4d44-bea9-cd159c2ca5fa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75bc8e2-8e8e-4883-be9c-b716842c5277 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f98c3424-1c43-43e4-8bca-2e3430f50c63 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a20478-5f33-4ecd-b5d3-dbba855e5f6b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4953df7b-ccdb-452c-8699-5fd7259609b4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc7ba02c-bdbb-5136-e053-2995a90ac545 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f6faeb-52b5-4b04-bf34-de5db8eb46dc (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f89c7c9-4c25-4ba2-ad90-5aeadb48f214 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f14ced9-c16c-905a-e053-2a91aa0a031e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00eb367-d7cc-42fa-91af-a1a5f90dbb41 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:133a4b65-762b-4712-baba-2442546f0379 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973bdc9b-6421-7e00-e2b6-3cce036d363e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddec2943-483d-403a-838c-cbdb6eefe0a1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652cb30f-4368-4009-93a3-3a0d2a365f42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a4aa63-0877-40e5-94c4-ea487db5691d (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
Atomoxetine has a half-life of about 5 hours.
Projected row 133
- Medicine slug
- atomoxetine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 50
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:309de576-c318-404a-bc15-660c2b1876fb (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours -- N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetine c
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16096e9c-2dcd-4c84-a1a8-1c85d6d6898c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
C max : Decreased 21% T max : Delayed 1 hour Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b757805-eabf-4301-85be-7a3e38f6b187 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetine c
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d3d8cf-7f3b-479e-bd9f-e204d4118517 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
C max : Decreased 21% T max : Delayed 1 hour Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:132852a6-5bff-15dd-255c-98309dd83630 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours -- N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetinec
Projected row 134
- Medicine slug
- atomoxetine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 50
- Source count
- 45
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 45
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 45 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7f78a37-d525-42b7-813a-fa3e18ae7b74 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d7ea8f7-981c-4acc-aeaf-7516325bfc0c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa109260-6d4c-429c-9957-19cbe0e34485 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402711d7-bd44-4f2a-ad2b-4756cdc68645 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793928fb-fbcb-4fc6-90d4-f8a15e6b1f93 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb2a8f6-0816-47b1-830a-ef23e97d498f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d26aff3-72a7-4a5b-a6fe-44dc8a08b196 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0782204e-56a3-4439-9fb8-194da9487049 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24bb7238-7e12-48d1-a572-2c753e69f604 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2614df7e-0b16-4b03-883e-141d4ec34b35 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4fe9217-1853-4f8b-9a93-77e511554ca1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1f858c-8721-49e3-be8b-bf180e89ff42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2c12e4-563c-417e-bee1-6d8c51e75af4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9df4617-b406-70ba-e053-2995a90a28e8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14f2804d-2914-4dd9-86c0-d084fcfd7e50 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd1d85-fbc1-4309-9365-58bacf108f5b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cceab35-dc4a-40bc-a245-10b64820e217 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f266ab7b-5a68-42b5-b204-e3249bea0aed (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96855061-440f-4c99-a152-cf8da8e2b1b3 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7002d75-edad-4141-91bf-7eebf50ad1aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e9e305-8d99-4234-b531-6ade177768b7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab8d905-e890-4e91-a730-3e5d12f5c23f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdcc267-d6ae-41ee-97d9-2c7596545ce8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6542d69-d0a2-4663-9172-943f9f6f5325 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e787cc2-5d0f-f231-e053-2a95a90ae99a (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b42f0c-a183-478b-bced-652dc12b33ec (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90f45a1e-f79f-468f-b21b-5dc82f5717aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10d36b32-0202-4c03-8a1a-cd5d53f231e7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b10860-aa08-4480-816c-c207819e5f9e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14fb8a4c-c2bf-4d44-bea9-cd159c2ca5fa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75bc8e2-8e8e-4883-be9c-b716842c5277 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f98c3424-1c43-43e4-8bca-2e3430f50c63 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a20478-5f33-4ecd-b5d3-dbba855e5f6b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4953df7b-ccdb-452c-8699-5fd7259609b4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc7ba02c-bdbb-5136-e053-2995a90ac545 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10 fold higher AUCs, 5 fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f6faeb-52b5-4b04-bf34-de5db8eb46dc (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f89c7c9-4c25-4ba2-ad90-5aeadb48f214 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f14ced9-c16c-905a-e053-2a91aa0a031e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00eb367-d7cc-42fa-91af-a1a5f90dbb41 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:133a4b65-762b-4712-baba-2442546f0379 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973bdc9b-6421-7e00-e2b6-3cce036d363e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddec2943-483d-403a-838c-cbdb6eefe0a1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652cb30f-4368-4009-93a3-3a0d2a365f42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a4aa63-0877-40e5-94c4-ea487db5691d (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (Ems)].
Projected row 135
- Medicine slug
- atomoxetine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 50
- Source count
- 50
- Agreement rate
- 1
- Recorded readings
0.85 L/kg
- Numeric value
- 0.85
- Unit
- L/kg
- Source records
- 50
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 50 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92de0ca1-6a02-4925-aefc-b32573d349a7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7f78a37-d525-42b7-813a-fa3e18ae7b74 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d7ea8f7-981c-4acc-aeaf-7516325bfc0c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:309de576-c318-404a-bc15-660c2b1876fb (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours -- N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetine c
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa109260-6d4c-429c-9957-19cbe0e34485 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:402711d7-bd44-4f2a-ad2b-4756cdc68645 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:793928fb-fbcb-4fc6-90d4-f8a15e6b1f93 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb2a8f6-0816-47b1-830a-ef23e97d498f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16096e9c-2dcd-4c84-a1a8-1c85d6d6898c (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
C max : Decreased 21% T max : Delayed 1 hour Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b757805-eabf-4301-85be-7a3e38f6b187 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetine c
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1d26aff3-72a7-4a5b-a6fe-44dc8a08b196 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0782204e-56a3-4439-9fb8-194da9487049 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24bb7238-7e12-48d1-a572-2c753e69f604 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2614df7e-0b16-4b03-883e-141d4ec34b35 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4fe9217-1853-4f8b-9a93-77e511554ca1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1f858c-8721-49e3-be8b-bf180e89ff42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2c12e4-563c-417e-bee1-6d8c51e75af4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9df4617-b406-70ba-e053-2995a90a28e8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14f2804d-2914-4dd9-86c0-d084fcfd7e50 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd1d85-fbc1-4309-9365-58bacf108f5b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cceab35-dc4a-40bc-a245-10b64820e217 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f266ab7b-5a68-42b5-b204-e3249bea0aed (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96855061-440f-4c99-a152-cf8da8e2b1b3 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7002d75-edad-4141-91bf-7eebf50ad1aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e9e305-8d99-4234-b531-6ade177768b7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab8d905-e890-4e91-a730-3e5d12f5c23f (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffdcc267-d6ae-41ee-97d9-2c7596545ce8 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6542d69-d0a2-4663-9172-943f9f6f5325 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e787cc2-5d0f-f231-e053-2a95a90ae99a (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35b42f0c-a183-478b-bced-652dc12b33ec (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90f45a1e-f79f-468f-b21b-5dc82f5717aa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10d36b32-0202-4c03-8a1a-cd5d53f231e7 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19b10860-aa08-4480-816c-c207819e5f9e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14fb8a4c-c2bf-4d44-bea9-cd159c2ca5fa (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75bc8e2-8e8e-4883-be9c-b716842c5277 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f98c3424-1c43-43e4-8bca-2e3430f50c63 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a20478-5f33-4ecd-b5d3-dbba855e5f6b (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4953df7b-ccdb-452c-8699-5fd7259609b4 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:72d3d8cf-7f3b-479e-bd9f-e204d4118517 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
C max : Decreased 21% T max : Delayed 1 hour Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours - N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc7ba02c-bdbb-5136-e053-2995a90ac545 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47f6faeb-52b5-4b04-bf34-de5db8eb46dc (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f89c7c9-4c25-4ba2-ad90-5aeadb48f214 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f14ced9-c16c-905a-e053-2a91aa0a031e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00eb367-d7cc-42fa-91af-a1a5f90dbb41 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:133a4b65-762b-4712-baba-2442546f0379 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:132852a6-5bff-15dd-255c-98309dd83630 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
T max : Delayed 3 hours Distribution Protein Binding 98% Volume of distribution 0.85 L/kg Elimination Atomoxetine half-life 5.2 hours 21.6 hours Atomoxetine apparent oral clearance 0.35 L/hr/kg 0.03 L/hr/kg 4-Hydroxyatomoxetine half-life 6 to 8 hours -- N-Desmethylatomoxetine half-life 6 to 8 hours 34 to 40 hours Metabolism Primary metabolic pathways CYP2D6 Other CYP enzymes 4-Hydroxyatomoxetinec
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:973bdc9b-6421-7e00-e2b6-3cce036d363e (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddec2943-483d-403a-838c-cbdb6eefe0a1 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652cb30f-4368-4009-93a3-3a0d2a365f42 (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97a4aa63-0877-40e5-94c4-ea487db5691d (opens source in a new tab)
Atomoxetine label
Version not recorded · Effective date not recorded
The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water.
Projected row 136
- Medicine slug
- atorvastatin
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 242
- Source count
- 242
- Agreement rate
- 1
- Recorded readings
14%
- Numeric value
- 14
- Unit
- %
- Source records
- 242
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 242 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd56a76b-5570-46a7-9399-fc110d913bf9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16b3805-7e60-447c-b3df-7a9392b63c99 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b22973-cb9a-473e-a240-112b3e84e97c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01eadde8-37f3-4474-995f-22c1a65adf12 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5b85cf-d8a0-e4d7-e053-2a95a90aad67 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0732bc4-702d-f566-e053-2a95a90a1d69 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:862f58d1-476c-2c90-e053-2991aa0ab821 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:862f9f27-c645-2d2e-e053-2991aa0a96b9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d916667-7b3e-ea20-e063-6294a90a52da (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac98cfd7-fd4c-4fe1-91f3-50a0e232364f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f9b462-f08e-483c-9b64-b7e4c8d46927 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46eeb12f-7e38-4828-b7d1-26b6155bc64a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:635addf1-2024-4675-8d3c-380dc4548fbd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f3e4e0-5407-4831-9885-3a37e72356c0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4185ea4-8fc1-4af5-99b1-6e49f0c46463 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9cb8d9-b367-464d-9bcd-6de8de2b6c23 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e6a3b6b-5536-434e-bd1d-7dc7256704ce (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f94ca58-c4bf-ac6c-e063-6394a90adba4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20f820ba-9600-4b51-bf23-8c99e815674c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2d8b5e9-6ff2-4efa-ab01-e13df29f7371 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61c29f52-7dcd-44ac-a8aa-4f54f0901f04 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed57fc60-ecb2-419e-b09f-3c518dcf3d04 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303989c9-823e-4bcb-a7b3-7024fd0d3a38 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10e766cc-c3fd-4584-a0d7-652c516e828c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b8c55ef-160d-42df-95d1-c008f1182e3e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:514fcba1-713c-4aeb-be8c-369fcf9b4ffe (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc2dd41-a465-45b6-a80a-67c41af29cf8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1935ab1-051b-7081-e053-2995a90a0901 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:901550e6-22be-68c9-eb86-f85a9c9dd998 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a34d3c72-ce91-47c7-86a1-f32caaed2c47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5868d3c2-ae17-4a7e-9580-7c3cf9bf009e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acbbd2c4-60bd-4e01-ad7a-b9b3178569f0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e014adf-251e-126e-e053-2995a90a05bf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ee8b455-625c-ead6-e053-2a95a90aed29 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d11f845-8e56-4251-8a1f-8f4b3843ea62 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31ccef91-ca32-61be-e063-6394a90a1065 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e60880-091a-4df7-8696-6e6c42a490e2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71cd9b85-4914-4b0b-97db-7aaf25983211 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33838d7-4e5e-4079-9d3d-00c2048cf776 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ff0d618-cde4-49ae-8bcb-98dafc3ecdba (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f8ca507-b784-4d18-8d3e-d7d68072c416 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993c39c2-afe6-4b92-9251-5695f4524a70 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c58bf4a-4a92-4db8-89bc-4de1b5831efc (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ef8f1-6b5f-234b-e063-6294a90ad2d3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc448f40-421c-490f-8c39-fa8135507973 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dcc58a-9f23-045d-e063-6394a90abda6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1914264b-4c95-4066-91ca-b5c91d8b741e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3084cae-db82-4e6f-e053-2995a90aa36a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46df076d-4e98-6faa-e054-00144ff8d46c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6600f22e-d303-4fe3-8212-accd6fb06e62 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3497ad6-b549-4144-b57f-b2088ad80b09 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149322ec-9ee6-2223-e063-6294a90a8aac (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e91c673d-c26c-4ff1-90d2-2b9d47a8d771 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09cb8375-075c-47e8-a4eb-8ac667ed849e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e74278b6-31fc-48d4-97b7-ba500e9e15fb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786388d-ac8d-4646-9fe4-b33e8fda86b2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b9a5a36-7814-4d19-b146-01e819676ae2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c1083b9-7a20-475d-ba12-4f5d0b53e601 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:510426cd-63fa-4ead-81d9-0b2f4e3c1052 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e52b4b11-9618-4787-ae67-44e4a3166dfb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d068ed-f9d2-4fd1-9755-b76bea89725e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85c38e0b-3d0b-4b04-990a-ed077a4c43e4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ec97c59-9d17-45f8-93f9-2c1f0361cb75 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4154300-65d4-4e31-97ad-b8d086c676e2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c435528-4c44-44c6-bb10-049a72533c2f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbeb2aa0-24a2-430f-b456-34a4e63e1817 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c658654-87ee-b52a-e063-6294a90a11d6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51f23212-a10d-4cfa-e054-00144ff88e88 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d93e3c4-59cc-cff4-e063-6394a90a8f7f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ade00fd-5eb4-f67a-e063-6294a90a9112 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee2ddb-851e-15ad-e063-6394a90a173a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:271409d0-5500-4ed0-8730-5a93226a2191 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54f93ed0-64ef-46bb-aab6-a8dd5dc4c035 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:330d488b-794d-416b-8ec7-073946e3fdf5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7cc5704-2131-4bcb-9ff0-33a79a8167bd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76b9e48-3ef7-e15a-e053-6394a90aed58 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5327cf20-81e0-4b46-8c86-88c0ddd19c5f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db32eb1a-d282-47df-afa2-f250e3c67e71 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:632ddd78-9e76-4230-944d-dff85d945238 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652f77a0-2145-896d-c760-e99e87507161 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60d51f39-8086-4434-affe-88ab8ca0c7e5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b3c3043-9af6-48eb-8b10-528e58c88e48 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e20a00c-b373-3a8c-e063-6294a90a637b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aee307d6-b3fa-424f-8656-1f30ff413e95 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634ec8e3-6d83-4cb2-90a3-fc9c973b06bf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:103cc381-3266-409d-bdc2-1de620bae355 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5767370-15a2-45e5-b980-7af9523aea7b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77675dc3-868d-42a3-a179-80372a23e0c8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de8f2c55-44d2-4e01-b7f2-dfb24f1f8760 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1a840cf-47aa-b931-e053-2a95a90a1047 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c1e9bf3-ef52-4053-933d-5a5f7405e642 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cd9999b-e18f-09de-e063-6294a90a108b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2de6b9b3-8f3c-599e-e063-6394a90aee60 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b839619-1805-c227-91bf-182f5b966ba4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f2152b6-790c-aa4a-e063-6294a90a3b18 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9adb9e4-c495-9530-e5e3-7e3b01d53e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55ad4a90-d177-4cce-b7ec-cb75067f6c14 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4509aa67-06d4-41d1-80b6-c9bd8ad0bf07 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd216f5d-f319-7d8d-e053-2a95a90aa9ce (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e59aa97-5480-41e0-86b0-047e648b976d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b1578a-70cc-6c58-e063-6394a90a0d1b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c5823ce-ed5c-356c-e063-6394a90aa15d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:536b5e0d-1bb9-4c9d-a588-460d7647308b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e873d38c-4bda-4101-be98-85b1601d09f7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6233cf-5b4e-5fbe-e053-2a95a90a0a80 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:124c111c-9272-eca9-e063-6394a90a0ad5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da6b77a5-2093-b7f7-e053-2995a90ab10d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:173474b6-26b4-46f2-a12a-64753ae5e905 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0a0feb6-84f0-4693-a11f-eb4f7ae0a87d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ba8fd9-aa40-466c-81bd-a87b364e9a1a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd0227-90a5-cdf6-e063-6294a90af661 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f84fd12-3e13-47b0-a628-d22a7c4ac3c0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c2272c5-f1ef-4d1b-a99e-45dd3cde08a9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:766690b2-9784-4496-9cf3-d5584ae605de (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f0df8b-6069-4941-87e9-2c57c8dfddfa (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1923c91e-c6dd-4446-aabd-70a0c6aa1a82 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb1a527-3b4d-4fd4-9e38-b231ad5d6d8f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa2d8d38-dbd0-43fd-e053-6294a90a4e94 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e8e69c-590f-4f74-82e1-199d8d14fa80 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fffae44-e536-9645-e063-6394a90a7ce5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30b9250c-00f6-cc7b-e063-6294a90a5a0e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85fbaf22-017b-4163-b33e-c6594994859b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25c8f92f-9cb6-482b-82e1-16ad7c94e7b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44a39b5a-77b6-42e8-9319-df21d3678e02 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66df5c0b-be89-4fc7-8f8d-c7689952c662 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8b186e4-28c2-4bf9-8964-5a5f3ca3a2da (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1b9e56b-1632-4450-b1ca-d8bcbba3fd7c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21234914-e1bb-4118-8f81-4ab4a59e9e1e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ea6235f-633c-af0b-e063-6294a90aad6d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60cc18b-0631-4cf0-b021-9f52224ece65 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75ea68e0-12e2-4e27-876f-f24f6e33a0b7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed0d5c17-0481-4d6b-8051-8d6e47f49ce5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f55cb6-a41b-dd27-e053-2a95a90aaeb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ed5fd35-8212-4eb4-bf44-aeca788e4e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:107d7aed-582d-4296-99e9-ec63c41a594c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18fe5990-399d-416c-852f-e14974317b8b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7fbe2a-1f7a-4944-b589-87ca05af7481 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d77e155c-403d-449e-bafd-11c9bd4974dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbbdd932-a43b-4e88-af6d-cfe994c941b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95729689-8055-45ae-e053-2995a90a919f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0835fa8-bd55-33bd-e053-2a95a90a96b1 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47709fe3-88d3-4d2e-b9db-a06dc1c2c7d4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a20bac35-a3d7-4e97-95c2-2502107d61c2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2035c49b-f319-4dce-bf1c-c2f64e786fb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fb1a276-8253-49f0-930e-6e158d643500 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b70f79-45a3-0869-e053-2a95a90a3cdb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e06b20d-cc5d-46eb-991b-5972248de3af (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6bc1ac6-c96c-4ecf-9935-733587ad6107 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d552a6f-d7a2-4dba-8e71-2b97b4ee2faf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a519e355-84f0-40d1-b586-e6e8eadb5b0f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7bb4aac-f716-4dd9-a6d7-6f37e865b843 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52f99e39-fb92-e9f5-e063-6294a90a1b6a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b94b6f4-6f64-4551-abcb-8e845fb13813 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf960d1-8bf9-64c6-1e70-8aa33b0ce549 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f00a83aa-3f1d-566d-b9bb-f396f22a27cb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1272aada-9a5b-4397-bb65-9398927aa325 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4847b761-30a5-0a1a-e063-6294a90ad02b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7af3b3a-b73e-41ee-80e3-2be036672bb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d97df6ad-87ca-46ec-8de7-4a958ab3b463 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ad89657-cc95-44a0-af6a-ee756526aa10 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51730b09-24e8-41c8-9fec-813f8a64b433 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afe2137-b8b6-4506-818a-e5fadb2aee51 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3af6315-08b5-4ff9-80ae-2984f0598611 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b2d0de1-50f0-4356-aa79-88696be8ac3d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8a72abf-1d43-47e1-88e8-c3c5cc4ba163 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7353f9ef-6f79-4522-886a-7a8ae4eb867e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32c8a4f-dee9-86a0-e053-2995a90a3388 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c095d497-0634-6413-e053-2a95a90aa67f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b687ba81-cb24-bbdf-5dd9-ab0e53dd480b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595ab888-6b55-4642-a32f-e8521821ed81 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c06fa9-ec26-5fa6-e063-6294a90a337f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0bbab86-6789-4ffb-8f84-ee91b69fdb34 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a7594ca-30be-4350-827f-ef745a2a7e18 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d57720ab-9f83-4da9-a57f-0d55e00a605c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e78ba844-97a6-4602-92b6-8190028b826d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2bad30-e7cf-c48a-e063-6294a90a5f47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0e2a5d0-1aa3-e131-e053-2a95a90a9870 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12751ca4-cde3-92dd-e063-6294a90a4e9d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba7a8604-93bb-4b82-b160-328ed17f89f9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b490414a-35e7-fded-e053-2a95a90aca8d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25015637-c825-487c-ac33-c5ac46a4732f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a132b72-5318-43ab-881d-a2e51bd20bdc (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fb2d51e-360c-40a3-8072-f22893890a51 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5412835b-27c6-461f-97b9-b5bf03afe7f2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e0e9e7-447d-4d9d-847e-46d68a77db2d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:395dbb88-5889-c91c-e063-6394a90a8daf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a7c3b3-f87e-4112-9998-578b2613da47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:befeea30-acf5-425d-bdea-5c79a9ebfad8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a102dd8f-25c8-48fa-8244-2d1675f1e1b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bd0f0ec-f7a3-4403-9a1a-11f18213631f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a9e58f-567e-30cc-e063-6294a90a290f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d8508b-aa98-cd89-5991-e2b5f982b6c6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cc6240a-58d3-4bca-aa1e-662228957f75 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff3e5db-d15f-4eb0-b9ed-7961b4e078e4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e931003a-3a8d-48b9-b13f-e620017303f6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dbeae00-89ab-48a6-9e57-8048facb2294 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3f27113-785c-419e-955a-d6782fade438 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c59ba4-1cb7-e23f-e063-6294a90a1683 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7e8c8d2-b74e-6afd-e053-6394a90af83e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:498ef8e6-3366-42f4-99fe-b3e1dedae887 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed8e76a5-6b40-47fe-9018-25bfe690a4dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e6b63f-0a20-404a-8915-2f698877a96b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:694a6a7f-9d46-46b0-9329-ad8c2bd5e403 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c67a15c-53b7-f431-e063-6394a90acc50 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:258d8737-0b80-7d80-e063-6394a90adc8e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e9151aa-053f-a17d-e063-6294a90afea5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af38f580-ce13-436a-a7e3-853c5ac8e540 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec1d1722-d035-4a8b-b3ab-d2d93f2fd4bb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9271942d-0151-4434-80de-bbccd8868c9c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15094eb-3161-441e-b8ea-c33db2af6b50 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e24e7cb-1949-6686-e063-6394a90a4760 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd26679f-f8ff-41d2-a384-bd1f66f8a614 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:606368de-dea3-4871-aa61-c00e77ed386f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e583569-499d-4f20-87ca-84e7d9868d22 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51e24220-3374-4e5e-9a8d-4113002c5bed (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:200c1994-9327-e02c-e063-6394a90a593d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9168df23-4260-46be-9556-8b037af0ea28 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d076309f-313a-1c71-e053-2995a90a7bb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:957feff4-5005-4eea-bbe2-7232be65b0eb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab0bcac-10a3-4178-9674-3730683a4183 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0b4f1a2-0082-4150-8f2b-e7440252b675 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1adc3c12-1a78-33a0-e063-6294a90a486a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251828ae-7519-35c2-e063-6394a90a71ea (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b070d1-217a-413b-9350-e2387c5c282a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ace2c37e-b525-4fe7-8316-9bd3fa4a092c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23ac06e0-556c-c640-e063-6394a90a931d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d203e05-1fe6-4262-9d66-b461f84c4672 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00afce9b-48c9-487a-a738-e359c005c707 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:604a011e-6c64-4895-8f6e-d28f119c4c22 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e959b07b-3e6c-44cc-9a6d-c6689d393e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06abf2dc-5ebd-4d42-b43c-7deeb93925dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811e6733-fa82-4b41-b426-fe24aa70e601 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e10adb3-8d3a-412f-ae56-d9b9bed4641f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf35034d-27ab-4263-a9ed-c7cee1a4fb0a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:112ae40c-b612-405b-8f68-6d4bf09f9440 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52561b3e-c20f-3536-e063-6394a90a6198 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8821431a-c387-4b75-9540-f92bd455e961 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f76cd3b-fbfa-a193-e063-6294a90a1b32 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86841382-4229-4e03-958e-3ac22639efd4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd1c5da-67fb-4412-acb5-4d4c74a43654 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
Projected row 137
- Medicine slug
- atorvastatin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 242
- Source count
- 242
- Agreement rate
- 1
- Recorded readings
381 liters
- Numeric value
- 381
- Unit
- L
- Source records
- 242
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 242 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09c6c750-ae05-459f-83e8-4a9e4fd85212 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd56a76b-5570-46a7-9399-fc110d913bf9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b16b3805-7e60-447c-b3df-7a9392b63c99 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1b22973-cb9a-473e-a240-112b3e84e97c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01eadde8-37f3-4474-995f-22c1a65adf12 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5b85cf-d8a0-e4d7-e053-2a95a90aad67 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0732bc4-702d-f566-e053-2a95a90a1d69 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:862f58d1-476c-2c90-e053-2991aa0ab821 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:862f9f27-c645-2d2e-e053-2991aa0a96b9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d916667-7b3e-ea20-e063-6294a90a52da (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac98cfd7-fd4c-4fe1-91f3-50a0e232364f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57f9b462-f08e-483c-9b64-b7e4c8d46927 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46eeb12f-7e38-4828-b7d1-26b6155bc64a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:635addf1-2024-4675-8d3c-380dc4548fbd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1f3e4e0-5407-4831-9885-3a37e72356c0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4185ea4-8fc1-4af5-99b1-6e49f0c46463 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d9cb8d9-b367-464d-9bcd-6de8de2b6c23 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e6a3b6b-5536-434e-bd1d-7dc7256704ce (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f94ca58-c4bf-ac6c-e063-6394a90adba4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20f820ba-9600-4b51-bf23-8c99e815674c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2d8b5e9-6ff2-4efa-ab01-e13df29f7371 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61c29f52-7dcd-44ac-a8aa-4f54f0901f04 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed57fc60-ecb2-419e-b09f-3c518dcf3d04 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:303989c9-823e-4bcb-a7b3-7024fd0d3a38 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10e766cc-c3fd-4584-a0d7-652c516e828c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters. atorvastatin calcium is ≥98% bound to plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b8c55ef-160d-42df-95d1-c008f1182e3e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:514fcba1-713c-4aeb-be8c-369fcf9b4ffe (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cc2dd41-a465-45b6-a80a-67c41af29cf8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1935ab1-051b-7081-e053-2995a90a0901 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:901550e6-22be-68c9-eb86-f85a9c9dd998 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a34d3c72-ce91-47c7-86a1-f32caaed2c47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5868d3c2-ae17-4a7e-9580-7c3cf9bf009e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acbbd2c4-60bd-4e01-ad7a-b9b3178569f0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e014adf-251e-126e-e053-2995a90a05bf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ee8b455-625c-ead6-e053-2a95a90aed29 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d11f845-8e56-4251-8a1f-8f4b3843ea62 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31ccef91-ca32-61be-e063-6394a90a1065 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e60880-091a-4df7-8696-6e6c42a490e2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71cd9b85-4914-4b0b-97db-7aaf25983211 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a33838d7-4e5e-4079-9d3d-00c2048cf776 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ff0d618-cde4-49ae-8bcb-98dafc3ecdba (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f8ca507-b784-4d18-8d3e-d7d68072c416 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993c39c2-afe6-4b92-9251-5695f4524a70 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c58bf4a-4a92-4db8-89bc-4de1b5831efc (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ef8f1-6b5f-234b-e063-6294a90ad2d3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc448f40-421c-490f-8c39-fa8135507973 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dcc58a-9f23-045d-e063-6394a90abda6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1914264b-4c95-4066-91ca-b5c91d8b741e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3084cae-db82-4e6f-e053-2995a90aa36a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46df076d-4e98-6faa-e054-00144ff8d46c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6600f22e-d303-4fe3-8212-accd6fb06e62 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3497ad6-b549-4144-b57f-b2088ad80b09 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:149322ec-9ee6-2223-e063-6294a90a8aac (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e91c673d-c26c-4ff1-90d2-2b9d47a8d771 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09cb8375-075c-47e8-a4eb-8ac667ed849e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e74278b6-31fc-48d4-97b7-ba500e9e15fb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9786388d-ac8d-4646-9fe4-b33e8fda86b2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b9a5a36-7814-4d19-b146-01e819676ae2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c1083b9-7a20-475d-ba12-4f5d0b53e601 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:510426cd-63fa-4ead-81d9-0b2f4e3c1052 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e52b4b11-9618-4787-ae67-44e4a3166dfb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d068ed-f9d2-4fd1-9755-b76bea89725e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85c38e0b-3d0b-4b04-990a-ed077a4c43e4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ec97c59-9d17-45f8-93f9-2c1f0361cb75 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4154300-65d4-4e31-97ad-b8d086c676e2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c435528-4c44-44c6-bb10-049a72533c2f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbeb2aa0-24a2-430f-b456-34a4e63e1817 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c658654-87ee-b52a-e063-6294a90a11d6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51f23212-a10d-4cfa-e054-00144ff88e88 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d93e3c4-59cc-cff4-e063-6394a90a8f7f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ade00fd-5eb4-f67a-e063-6294a90a9112 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eee2ddb-851e-15ad-e063-6394a90a173a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:271409d0-5500-4ed0-8730-5a93226a2191 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54f93ed0-64ef-46bb-aab6-a8dd5dc4c035 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:330d488b-794d-416b-8ec7-073946e3fdf5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7cc5704-2131-4bcb-9ff0-33a79a8167bd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f76b9e48-3ef7-e15a-e053-6394a90aed58 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5327cf20-81e0-4b46-8c86-88c0ddd19c5f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db32eb1a-d282-47df-afa2-f250e3c67e71 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:632ddd78-9e76-4230-944d-dff85d945238 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:652f77a0-2145-896d-c760-e99e87507161 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60d51f39-8086-4434-affe-88ab8ca0c7e5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b3c3043-9af6-48eb-8b10-528e58c88e48 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e20a00c-b373-3a8c-e063-6294a90a637b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aee307d6-b3fa-424f-8656-1f30ff413e95 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:634ec8e3-6d83-4cb2-90a3-fc9c973b06bf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:103cc381-3266-409d-bdc2-1de620bae355 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5767370-15a2-45e5-b980-7af9523aea7b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77675dc3-868d-42a3-a179-80372a23e0c8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de8f2c55-44d2-4e01-b7f2-dfb24f1f8760 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1a840cf-47aa-b931-e053-2a95a90a1047 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c1e9bf3-ef52-4053-933d-5a5f7405e642 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cd9999b-e18f-09de-e063-6294a90a108b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2de6b9b3-8f3c-599e-e063-6394a90aee60 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b839619-1805-c227-91bf-182f5b966ba4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f2152b6-790c-aa4a-e063-6294a90a3b18 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9adb9e4-c495-9530-e5e3-7e3b01d53e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55ad4a90-d177-4cce-b7ec-cb75067f6c14 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4509aa67-06d4-41d1-80b6-c9bd8ad0bf07 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd216f5d-f319-7d8d-e053-2a95a90aa9ce (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e59aa97-5480-41e0-86b0-047e648b976d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13b1578a-70cc-6c58-e063-6394a90a0d1b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c5823ce-ed5c-356c-e063-6394a90aa15d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:536b5e0d-1bb9-4c9d-a588-460d7647308b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e873d38c-4bda-4101-be98-85b1601d09f7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6233cf-5b4e-5fbe-e053-2a95a90a0a80 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium tablets are approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:124c111c-9272-eca9-e063-6394a90a0ad5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da6b77a5-2093-b7f7-e053-2995a90ab10d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:173474b6-26b4-46f2-a12a-64753ae5e905 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium tablets is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0a0feb6-84f0-4693-a11f-eb4f7ae0a87d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ba8fd9-aa40-466c-81bd-a87b364e9a1a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47cd0227-90a5-cdf6-e063-6294a90af661 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f84fd12-3e13-47b0-a628-d22a7c4ac3c0 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c2272c5-f1ef-4d1b-a99e-45dd3cde08a9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:766690b2-9784-4496-9cf3-d5584ae605de (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44f0df8b-6069-4941-87e9-2c57c8dfddfa (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1923c91e-c6dd-4446-aabd-70a0c6aa1a82 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ccdb6f3-22c7-5b48-46bc-ce4a4c65eb4d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbb1a527-3b4d-4fd4-9e38-b231ad5d6d8f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa2d8d38-dbd0-43fd-e053-6294a90a4e94 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e8e69c-590f-4f74-82e1-199d8d14fa80 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fffae44-e536-9645-e063-6394a90a7ce5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30b9250c-00f6-cc7b-e063-6294a90a5a0e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85fbaf22-017b-4163-b33e-c6594994859b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25c8f92f-9cb6-482b-82e1-16ad7c94e7b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44a39b5a-77b6-42e8-9319-df21d3678e02 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66df5c0b-be89-4fc7-8f8d-c7689952c662 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8b186e4-28c2-4bf9-8964-5a5f3ca3a2da (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1b9e56b-1632-4450-b1ca-d8bcbba3fd7c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21234914-e1bb-4118-8f81-4ab4a59e9e1e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ea6235f-633c-af0b-e063-6294a90aad6d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a60cc18b-0631-4cf0-b021-9f52224ece65 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of LIPITOR is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75ea68e0-12e2-4e27-876f-f24f6e33a0b7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed0d5c17-0481-4d6b-8051-8d6e47f49ce5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f55cb6-a41b-dd27-e053-2a95a90aaeb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ed5fd35-8212-4eb4-bf44-aeca788e4e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:107d7aed-582d-4296-99e9-ec63c41a594c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18fe5990-399d-416c-852f-e14974317b8b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7fbe2a-1f7a-4944-b589-87ca05af7481 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d77e155c-403d-449e-bafd-11c9bd4974dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbbdd932-a43b-4e88-af6d-cfe994c941b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95729689-8055-45ae-e053-2995a90a919f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0835fa8-bd55-33bd-e053-2a95a90a96b1 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47709fe3-88d3-4d2e-b9db-a06dc1c2c7d4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a20bac35-a3d7-4e97-95c2-2502107d61c2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2035c49b-f319-4dce-bf1c-c2f64e786fb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fb1a276-8253-49f0-930e-6e158d643500 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b70f79-45a3-0869-e053-2a95a90a3cdb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e06b20d-cc5d-46eb-991b-5972248de3af (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium tablets are approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6bc1ac6-c96c-4ecf-9935-733587ad6107 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d552a6f-d7a2-4dba-8e71-2b97b4ee2faf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a519e355-84f0-40d1-b586-e6e8eadb5b0f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7bb4aac-f716-4dd9-a6d7-6f37e865b843 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52f99e39-fb92-e9f5-e063-6294a90a1b6a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b94b6f4-6f64-4551-abcb-8e845fb13813 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aaf960d1-8bf9-64c6-1e70-8aa33b0ce549 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f00a83aa-3f1d-566d-b9bb-f396f22a27cb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1272aada-9a5b-4397-bb65-9398927aa325 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4847b761-30a5-0a1a-e063-6294a90ad02b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7af3b3a-b73e-41ee-80e3-2be036672bb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d97df6ad-87ca-46ec-8de7-4a958ab3b463 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ad89657-cc95-44a0-af6a-ee756526aa10 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51730b09-24e8-41c8-9fec-813f8a64b433 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium tablets are approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afe2137-b8b6-4506-818a-e5fadb2aee51 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3af6315-08b5-4ff9-80ae-2984f0598611 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4b2d0de1-50f0-4356-aa79-88696be8ac3d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8a72abf-1d43-47e1-88e8-c3c5cc4ba163 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7353f9ef-6f79-4522-886a-7a8ae4eb867e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f32c8a4f-dee9-86a0-e053-2995a90a3388 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c095d497-0634-6413-e053-2a95a90aa67f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b687ba81-cb24-bbdf-5dd9-ab0e53dd480b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595ab888-6b55-4642-a32f-e8521821ed81 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53c06fa9-ec26-5fa6-e063-6294a90a337f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0bbab86-6789-4ffb-8f84-ee91b69fdb34 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a7594ca-30be-4350-827f-ef745a2a7e18 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d57720ab-9f83-4da9-a57f-0d55e00a605c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e78ba844-97a6-4602-92b6-8190028b826d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2bad30-e7cf-c48a-e063-6294a90a5f47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0e2a5d0-1aa3-e131-e053-2a95a90a9870 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12751ca4-cde3-92dd-e063-6294a90a4e9d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba7a8604-93bb-4b82-b160-328ed17f89f9 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b490414a-35e7-fded-e053-2a95a90aca8d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25015637-c825-487c-ac33-c5ac46a4732f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a132b72-5318-43ab-881d-a2e51bd20bdc (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fb2d51e-360c-40a3-8072-f22893890a51 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5412835b-27c6-461f-97b9-b5bf03afe7f2 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49e0e9e7-447d-4d9d-847e-46d68a77db2d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:395dbb88-5889-c91c-e063-6394a90a8daf (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8a7c3b3-f87e-4112-9998-578b2613da47 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:befeea30-acf5-425d-bdea-5c79a9ebfad8 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a102dd8f-25c8-48fa-8244-2d1675f1e1b3 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7bd0f0ec-f7a3-4403-9a1a-11f18213631f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium tablets is approximately 381 liters. atorvastatin calcium tablets is ≥98% bound to plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a9e58f-567e-30cc-e063-6294a90a290f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d8508b-aa98-cd89-5991-e2b5f982b6c6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cc6240a-58d3-4bca-aa1e-662228957f75 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fff3e5db-d15f-4eb0-b9ed-7961b4e078e4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e931003a-3a8d-48b9-b13f-e620017303f6 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3dbeae00-89ab-48a6-9e57-8048facb2294 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters. atorvastatin calcium is ≥98% bound to plasma proteins.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3f27113-785c-419e-955a-d6782fade438 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c59ba4-1cb7-e23f-e063-6294a90a1683 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7e8c8d2-b74e-6afd-e053-6394a90af83e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:498ef8e6-3366-42f4-99fe-b3e1dedae887 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed8e76a5-6b40-47fe-9018-25bfe690a4dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40e6b63f-0a20-404a-8915-2f698877a96b (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:694a6a7f-9d46-46b0-9329-ad8c2bd5e403 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2c67a15c-53b7-f431-e063-6394a90acc50 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:258d8737-0b80-7d80-e063-6394a90adc8e (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e9151aa-053f-a17d-e063-6294a90afea5 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af38f580-ce13-436a-a7e3-853c5ac8e540 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec1d1722-d035-4a8b-b3ab-d2d93f2fd4bb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9271942d-0151-4434-80de-bbccd8868c9c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15094eb-3161-441e-b8ea-c33db2af6b50 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e24e7cb-1949-6686-e063-6394a90a4760 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd26679f-f8ff-41d2-a384-bd1f66f8a614 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:606368de-dea3-4871-aa61-c00e77ed386f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e583569-499d-4f20-87ca-84e7d9868d22 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51e24220-3374-4e5e-9a8d-4113002c5bed (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:200c1994-9327-e02c-e063-6394a90a593d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9168df23-4260-46be-9556-8b037af0ea28 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d076309f-313a-1c71-e053-2995a90a7bb7 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution: Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:957feff4-5005-4eea-bbe2-7232be65b0eb (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ab0bcac-10a3-4178-9674-3730683a4183 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0b4f1a2-0082-4150-8f2b-e7440252b675 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1adc3c12-1a78-33a0-e063-6294a90a486a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:251828ae-7519-35c2-e063-6394a90a71ea (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b070d1-217a-413b-9350-e2387c5c282a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ace2c37e-b525-4fe7-8316-9bd3fa4a092c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23ac06e0-556c-c640-e063-6394a90a931d (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d203e05-1fe6-4262-9d66-b461f84c4672 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00afce9b-48c9-487a-a738-e359c005c707 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:604a011e-6c64-4895-8f6e-d28f119c4c22 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e959b07b-3e6c-44cc-9a6d-c6689d393e4c (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:06abf2dc-5ebd-4d42-b43c-7deeb93925dd (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:811e6733-fa82-4b41-b426-fe24aa70e601 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e10adb3-8d3a-412f-ae56-d9b9bed4641f (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf35034d-27ab-4263-a9ed-c7cee1a4fb0a (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:112ae40c-b612-405b-8f68-6d4bf09f9440 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52561b3e-c20f-3536-e063-6394a90a6198 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8821431a-c387-4b75-9540-f92bd455e961 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f76cd3b-fbfa-a193-e063-6294a90a1b32 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86841382-4229-4e03-958e-3ac22639efd4 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin calcium is approximately 381 liters.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd1c5da-67fb-4412-acb5-4d4c74a43654 (opens source in a new tab)
Atorvastatin label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.
Projected row 138
- Medicine slug
- atovaquone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 23
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
62.5 ± 35.3 hours
- Numeric value
- 62.5
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54423fee-da60-25dc-e063-6294a90a2552 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99a8a0c-2b42-4da0-8f5a-e963fc619e8b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e2297e-7cda-4abf-9fb7-8c67cb5638a3 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40331de7-819e-5965-e063-6294a90ac91d (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a43a2-bc26-4ee5-aa35-22a5477a7129 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9045ba6f-938e-4717-bfa2-a3efe52f04cd (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6086d3-6100-422a-bf23-e9610027749b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba3cad0d-cce9-424f-ba5c-557dba8bef12 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
The half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67 ± 33.4 to 77.6 ± 23.1 hours across trials following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ddcc33-729c-4d46-ae6b-2ee47978ba16 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
The half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67 ± 33.4 to 77.6 ± 23.1 hours across trials following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2445304e-4b4e-4358-b098-31f3c49c52ef (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d3715ed-6ddc-4c10-9d2c-9c80cb1dfd08 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b426b6bf-f07e-4580-97ae-dfca1ddf5b8f (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of MEPRON oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7398fcf-522a-488a-8dd6-051561f62804 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6770b85-54f8-4969-af02-7d81586be761 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0e29b5-a4c7-405c-a5b9-438729d9ba3a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc7bdd97-f780-4eed-80e0-72e70267b21a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b69156-e5de-c601-e063-6394a90afeae (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e2c4b-85aa-9b30-e063-6294a90a7bd9 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbfe1a9-df9b-79b0-e053-2995a90acc9b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27d64592-5078-6122-e063-6394a90ae074 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4124ad97-f6b9-8afb-e063-6294a90ab970 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ff20a-c363-4be0-9bc0-3081c163b63c (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff4f4fc-6307-f414-e053-2a95a90ac0de (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Elimination The mean (±SD) half-life of atovaquone was 62.5 ± 35.3 hours after IV administration and ranged from 67.0 ± 33.4 to 77.6 ± 23.1 hours following administration of atovaquone oral suspension.
Projected row 139
- Medicine slug
- atovaquone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 23
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
99.9%
- Numeric value
- 99.9
- Unit
- %
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54423fee-da60-25dc-e063-6294a90a2552 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99a8a0c-2b42-4da0-8f5a-e963fc619e8b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e2297e-7cda-4abf-9fb7-8c67cb5638a3 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40331de7-819e-5965-e063-6294a90ac91d (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a43a2-bc26-4ee5-aa35-22a5477a7129 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9045ba6f-938e-4717-bfa2-a3efe52f04cd (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6086d3-6100-422a-bf23-e9610027749b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba3cad0d-cce9-424f-ba5c-557dba8bef12 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ddcc33-729c-4d46-ae6b-2ee47978ba16 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2445304e-4b4e-4358-b098-31f3c49c52ef (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d3715ed-6ddc-4c10-9d2c-9c80cb1dfd08 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b426b6bf-f07e-4580-97ae-dfca1ddf5b8f (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7398fcf-522a-488a-8dd6-051561f62804 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6770b85-54f8-4969-af02-7d81586be761 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0e29b5-a4c7-405c-a5b9-438729d9ba3a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc7bdd97-f780-4eed-80e0-72e70267b21a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b69156-e5de-c601-e063-6394a90afeae (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e2c4b-85aa-9b30-e063-6294a90a7bd9 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbfe1a9-df9b-79b0-e053-2995a90acc9b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27d64592-5078-6122-e063-6394a90ae074 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4124ad97-f6b9-8afb-e063-6294a90ab970 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ff20a-c363-4be0-9bc0-3081c163b63c (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff4f4fc-6307-f414-e053-2a95a90ac0de (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 mcg/mL.
Projected row 140
- Medicine slug
- atovaquone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 23
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
0.60 ± 0.17 L/kg
- Numeric value
- 0.6
- Unit
- L/kg
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54423fee-da60-25dc-e063-6294a90a2552 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady-state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f99a8a0c-2b42-4da0-8f5a-e963fc619e8b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vdss) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73e2297e-7cda-4abf-9fb7-8c67cb5638a3 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vdss) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40331de7-819e-5965-e063-6294a90ac91d (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vdss) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8a43a2-bc26-4ee5-aa35-22a5477a7129 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9045ba6f-938e-4717-bfa2-a3efe52f04cd (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df6086d3-6100-422a-bf23-e9610027749b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba3cad0d-cce9-424f-ba5c-557dba8bef12 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03ddcc33-729c-4d46-ae6b-2ee47978ba16 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2445304e-4b4e-4358-b098-31f3c49c52ef (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vdss) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d3715ed-6ddc-4c10-9d2c-9c80cb1dfd08 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b426b6bf-f07e-4580-97ae-dfca1ddf5b8f (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7398fcf-522a-488a-8dd6-051561f62804 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady-state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6770b85-54f8-4969-af02-7d81586be761 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de0e29b5-a4c7-405c-a5b9-438729d9ba3a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc7bdd97-f780-4eed-80e0-72e70267b21a (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vdss) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16b69156-e5de-c601-e063-6394a90afeae (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2e2c4b-85aa-9b30-e063-6294a90a7bd9 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ddbfe1a9-df9b-79b0-e053-2995a90acc9b (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27d64592-5078-6122-e063-6394a90ae074 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4124ad97-f6b9-8afb-e063-6294a90ab970 (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady-state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31ff20a-c363-4be0-9bc0-3081c163b63c (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff4f4fc-6307-f414-e053-2a95a90ac0de (opens source in a new tab)
Atovaquone label
Version not recorded · Effective date not recorded
Distribution Following IV administration of atovaquone, the mean (±SD) volume of distribution at steady state (Vd ss ) was 0.60 ± 0.17 L/kg (n = 9).
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=130Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.